**Supplemental Material**

**Table S1.** Posttransplant cancer types among 1047 solid organ transplant recipients with one pretransplant cancer

|  |  |
| --- | --- |
| **Posttransplant cancer Type** | **N (%)** |
| Head and neck | 57 (4.86%) |
| Esophagus | 15 (1.28%) |
| Stomach | 19 (1.63%) |
| Colorectum | 70 (5.99%) |
| Anus | 11 (0.94%) |
| Liver and intrahepatic bile duct | 18 (1.54%) |
| Pancreas | 24 (2.05%) |
| Lung and pleura | 207 (17.7%) |
| Soft tissue including heart | 8 (0.68%) |
| Melanoma | 76 (6.50) |
| Other non-epithelial skin | 39 (3.34) |
| Breast | 71 (6.07) |
| Uterus | 11 (0.94) |
| Vulva and vagina | 11 (0.94%) |
| Prostate | 82 (7.01%) |
| Urinary Bladder | 32 (2.74%) |
| Kidney, Renal Pelvis, other urinary organs | 114 (9.75%) |
| Thyroid | 35 (2.99) |
| Non-Hodgkin lymphoma | 109 (9.32%) |
| Myeloma | 22 (1.88) |
| Acute myeloid leukemia | 16 (1.37) |
| Miscellaneous | 122 (9.84%) |
| **Total** | 1169 (100%) |

**Table S2.** Cancer-specific deaths confirmed by cancer registry, among solid organ transplant recipients with 1 pretransplant cancer

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Cancer that led to death, N (%)** | | |
|  |  | **Pretransplant cancer** | **Posttransplant cancer** | **Uncertain** |
| **Total** |  | 105 (34.3%) | 158 (51.6%) | 43 (14.1%) |
|  |  |  |  |  |
| **Characteristic of pretransplant cancer** |  |  |  |  |
|  |  |  |  |  |
| **Stage** |  |  |  |  |
| Local |  | 47 (23.9%) | 120 (60.9%) | 30 (15.2%) |
| Regional |  | 24 (50.0%) | 18 (37.5%) | 6 (12.5%) |
| Distant |  | 7 (58.3%) | 3 (25.0%) | 2 (16.7%) |
| Unknown |  | 27 (55.1%) | 17 (34.7%) | 5 (10.2%) |
|  |  |  |  |  |
| **Years from cancer diagnosis to transplant** |  |  |  |  |
| 0 - 1.99 |  | 29 (40.8%) | 31 (43.7%) | 11 (15.5%) |
| 2 - 4.99 |  | 31 (36.0%) | 45 (52.3%) | 10 (11.6%) |
| 5+ |  | 45 (30.2%) | 82 (55.0%) | 22 (14.8%) |
|  |  |  |  |  |
| **Cancer type** |  |  |  |  |
| Colorectum |  | 7 (30.4%) | 15 (65.2%) | 1 (4.3%) |
| Lung |  | 10 (76.9%) | 3 (23.1%) | 0 |
| Melanoma |  | 8 (47.1%) | 6 (35.3%) | 3 (17.6%) |
| Breast |  | 13 (36.1%) | 15 (41.7%) | 8 (22.2%) |
| Uterus |  | 0 | 4 (100%) | 0 |
| Prostate |  | 9 (15.0%) | 40 (66.7%) | 11 (18.3% |
| Kidney |  | 16 (33.3%) | 29 (60.4%) | 3 (6.3%) |
| Bladder |  | 1 (9.1%) | 7 (63.6%) | 3 (27.3%) |
| Thyroid |  | 0 | 4 (57.1%) | 3 (42.9%) |
| NHL/CLL |  | 5 (55.6%) | 3 (33.3%) | 1 (11.1%) |
| Myeloma |  | 8 (61.5%) | 3 (23.1%) | 2 (15.4%) |

Abbreviations: CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma